Detalles de la búsqueda
1.
Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer.
Ther Adv Med Oncol
; 10: 1758835918778297, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30023006
2.
A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.
Oncotarget
; 8(49): 85120-85135, 2017 Oct 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-29156708
3.
The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.
Oncotarget
; 7(46): 75518-75525, 2016 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27776352
Resultados
1 -
3
de 3
1
Próxima >
>>